A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major question of this trial is, if a haploidentical αß/CD19+ T-cell depleted HSCT can be a valid alternative to a MSD HSCT. The main challenge in non-malignant diseases is to offer a safe and GvHD-free HSCT without rejection.

NCT Number	NCT04201210
Lead Sponsor	University of Regensburg
Conditions	HbS Disease, Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disorders, Sickling Disorder Due to Hemoglobin S, Sickle Cell Disease
Enrollment	212 participants
Start Date	2021-06-30
Primary Completion	2028-03-31 (estimated)
Study Completion	2030-03-31 (estimated)
Updated on ClinicalTrials.gov	2024-05-13